Novel 2H-chromen-2-one derivatives of resveratrol: Design, synthesis, modeling and use as human monoamine oxidase inhibitors

European Journal of Medicinal Chemistry

Volumn 103, Issue , 2015, Pages 185-190

  Ruan, Ban Feng ^a   Cheng, Hui Jie ^a   Ren, Jing ^a   Li, Hong Lin ^a   Guo, Lu Lu ^a   Zhang, Xing Xing ^a   Liao, Chenzhong ^a  

^a HEFEI UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

2H chromen 2 one; Fragment based drug design; hMAO; Isoforms selectivity; Resveratrol

Indexed keywords

3 ((E) 3 (2 ((E) STYRYL)PHENYL)ACRYLOYL) 2H CHROMEN 2 ONE DERIVATIVE; COUMARIN; MONOAMINE OXIDASE INHIBITOR; PHENOL DERIVATIVE; RESVERATROL; SELEGILINE; UNCLASSIFIED DRUG; AMINE OXIDASE (FLAVIN CONTAINING); CHROMONE DERIVATIVE; STILBENE DERIVATIVE;

ARTICLE; DRUG DESIGN; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84941031353     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.08.055     Document Type: Article

References (30)

1. D.E. Edmondson, A. Mattevi, C. Binda, M. Li, F. Hubalek, Structure and mechanism of monoamine oxidase, Curr. Med. Chem. 11 (2004) 1983-1993.
2. J.C. Shih, K. Chen, M.J. Ridd, Monoamine oxidase: from genes to behavior, Annu. Rev. Neurosci. 22 (1999) 197-217.
3. S. Chajkowski-Scarry, J.M. Rimoldi, Monoamine oxidase A and B substrates: probing the pathway for drug development, Future Med. Chem. 6 (2014) 697-717.
4. S. Carradori, D. Secci, A. Bolasco, P. Chimenti, M. D'Ascenzio, Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential, Expert Opin. Ther. Pat. 22 (2012) 759-801.
5. M.B. Youdim, D. Edmondson, K.F. Tipton, The therapeutic potential of monoamine oxidase inhibitors, Nat. Rev. Neurosci. 7 (2006) 295-309.
6. J.A. Barsa, J.C. Saunders, A comparative study of tranylcypromine and paragyline, Psychopharmacologia 6 (1964) 295-298.
7. U. Bonnet, Moclobemide: therapeutic use and clinical studies, Cns Drug Rev. 9 (2003) 97-140.
8. S. Marconi, T. Zwingers, Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease, Eur. Rev. Med. Pharmacol. Sci. 18 (2014) 1879-1882.
9. E. Maccioni, S. Alcaro, R. Cirilli, S. Vigo, M.C. Cardia, M.L. Sanna, R. Meleddu, M. Yanez, G. Costa, L. Casu, P. Matyus, S. Distinto, 3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: a new scaffold for the selective inhibition of monoamine oxidase B, J. Med. Chem. 54 (2011) 6394-6398.
10. A.H. Schapira, Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects, CNS Drugs 25 (2011) 1061-1071.
11. Z.X. Pan, X. He, Y.Y. Chen, W.J. Tang, J.B. Shi, Y.L. Tang, B.A. Song, J. Li, X.H. Liu, New 2H-chromene-3-carboxamide derivatives: design, synthesis and use as inhibitors of hMAO, Eur. J. Med. Chem. 80 (2014) 278-284.
12. S. Carradori, R. Silvestri, New frontiers in selective human MAO-B inhibitors, J. Med. Chem. (2015).
13. B.F. Ruan, X.Q. Lu, J. Song, H.L. Zhu, Derivatives of resveratrol: potential agents in prevention and treatment of cardiovascular disease, Curr. Med. Chem. 19 (2012) 4175-4183.
14. X.M. Peng, G.L. Damu, C. Zhou, Current developments of coumarin compounds in medicinal chemistry, Curr. Pharm. Des. 19 (2013) 3884-3930.
15. C. Kontogiorgis, A. Detsi, D. Hadjipavlou-Litina, Coumarin-based drugs: a patent review (2008 - present), Expert Opin. Ther. Pat. 22 (2012) 437-454.
16. P.O. Patil, S.B. Bari, S.D. Firke, P.K. Deshmukh, S.T. Donda, D.A. Patil, A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease, Bioorg. Med. Chem. 21 (2013) 2434-2450.
17. L. Pisani, M. Catto, O. Nicolotti, G. Grossi, M. Di Braccio, R. Soto-Otero, E. Mendez-Alvarez, A. Stefanachi, D. Gadaleta, A. Carotti, Fine molecular tuning at position 4 of 2H-chromen-2-one derivatives in the search of potent and selective monoamine oxidase B inhibitors, Eur. J. Med. Chem. 70 (2013) 723-739.
18. L. Pisani, R. Farina, O. Nicolotti, D. Gadaleta, R. Soto-Otero, M. Catto, M. Di Braccio, E. Mendez-Alvarez, A. Carotti, In silico design of novel 2H-chromen-2-one derivatives as potent and selective MAO-B inhibitors, Eur. J. Med. Chem. 89 (2015) 98-105.
19. C. Liao, M. Sitzmann, A. Pugliese, M.C. Nicklaus, Software and resources for computational medicinal chemistry, Future Med. Chem. 3 (2011) 1057-1085.
20. C. Binda, M. Li, F. Hubalek, N. Restelli, D.E. Edmondson, A. Mattevi, Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9750-9755.
21. J.F. Chen, S. Steyn, R. Staal, J.P. Petzer, K. Xu, C.J. Van Der Schyf, K. Castagnoli, P.K. Sonsalla, N. Castagnoli Jr., M.A. Schwarzschild, 8-(3-Chlorostyryl) caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism, J. Biol. Chem. 277 (2002) 36040-36044.
22. F. Hubalek, C. Binda, A. Khalil, M. Li, A. Mattevi, N. Castagnoli, D.E. Edmondson, Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors, J. Biol. Chem. 280 (2005) 15761-15766.
23. B.F. Ruan, X. Lu, J.F. Tang, Y. Wei, X.L. Wang, Y.B. Zhang, L.S. Wang, H.L. Zhu, Synthesis, biological evaluation, and molecular docking studies of resveratrol derivatives possessing chalcone moiety as potential antitubulin agents, Bioorg. Med. Chem. 19 (2011) 2688-2695.
24. D.L. Murphy, F. Karoum, D. Pickar, R.M. Cohen, S. Lipper, A.M. Mellow, P.N. Tariot, T. Sunderland, Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline), J. Neural Transm. Suppl. 52 (1998) 39-48.
25. D. Bonivento, E.M. Milczek, G.R. McDonald, C. Binda, A. Holt, D.E. Edmondson, A. Mattevi, Potentiation of ligand binding through cooperative effects in monoamine oxidase B, J. Biol. Chem. 285 (2010) 36849-36856.
26. C. Binda, J. Wang, L. Pisani, C. Caccia, A. Carotti, P. Salvati, D.E. Edmondson, A. Mattevi, Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs, J. Med. Chem. 50 (2007) 5848-5852.
27. S.Y. Son, J. Ma, Y. Kondou, M. Yoshimura, E. Yamashita, T. Tsukihara, Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 5739-5744.
28. J. Ma, M. Yoshimura, E. Yamashita, A. Nakagawa, A. Ito, T. Tsukihara, Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors, J. Mol. Biol. 338 (2004) 103-114.
29. R.M. Geha, I. Rebrin, K. Chen, J.C. Shih, Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid, J. Biol. Chem. 276 (2001) 9877-9882.
30. C.Z. Liao, R.S. Yao, Diversity evolution and jump of Polo-like kinase 1 inhibitors, Sci. China Chem. 56 (2013) 1392-1401.